1824663-83-3

Uses

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].

in vivo

Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) shows potent antitumor activity in multiple xenograft models in mice^[1].

Animal Model:	SCID mice, RT4 xenograft model^[1]
Dosage:	5 mg/kg
Administration:	Intravenous injection, single dose
Result:	Caused significant inhibition.

Animal Model:	SCID mice, AG-B7 and AG-B8 xenograft model^[1]
Dosage:	0.25 and 0.5 mg/kg
Administration:	Intravenous injection, 2x per week for 2 or 3 weeks
Result:	Significantly reduced tumor volume.

Animal Model:	SCID mice, the lung xenograft model NCI-H322M^[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection, 2x per week for 3 weeks
Result:	Was able to cause 99% tumor growth inhibition.

References

[1] Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15(6):1301-10. DOI:10.1158/1535-7163.MCT-15-0570

Hazard Information

Uses

in vivo

References

Supplier